Ciprofloxacin in general practice

Ciprofloxacin Controlled-Solid Lipid Nanoparticles: Characterization, In Vitro Release, and Antibacterial Activity Assessment

“…In comparing the inhibitory zone of CIP in the CIPSTE formula for the two bacterial strains, it was concluded that CIP exhibits an inhibitory zone with P. aeruginosa and S. aureus . This could be due to the fact that CIP is more strongly effective on gram-negative than gram-positive bacteria [ 38 , 39 ]. The results showed that the control solution (free CIP) and physical mixture of CIP exhibited a maximum inhibition zone after 6 hours in the case of P. aeruginosa and S. aureus .…”

Development and Preparation of ciprofloxacin Drug Derivatives for Treatment of Microbial Contamination in Hospitals and Environment

“…Ciprofloxacin medication is a broad-variety fluoroquinolone antibiotic [5,6] secondhand in the dealing of a wide series (Oliphant C and Green . 2002) of slight to reasonable gram-(positive & negative) toxicities.,which is used to indulgence or inhibit (Stevens et al 2005.,Osmon et al 2013) certain infections affected through bacteria like gonorrhea;pneumonia [8][9][10][11] and toxicities (Vardakas K et al 2008.,Donaldson P et al 1994 or infection of the skin, bone, joint, stomach [12][13][14][15][16] region, and ( Karageorgopoulos et Prostate ciprofloxacin treatment is likewise used to delight or avoid and inhibit a serious infection that may be extent on tenacity [17][18][19][20][21][22] (Corrao G et al 2006 .,Liu X et al 2017) as portion of a bioterror round) and mouthful [23][24][25][26][27] (Bolhuis et al 2001 .,Pommier et al 2010.,Goossens et al 2007) anthrax [28] .…”

Novel 5-Nitrofuran-Tagged Imidazo-Fused Azines and Azoles Amenable by the Groebke–Blackburn–Bienaymé Multicomponent Reaction: Activity Profile against ESKAPE Pathogens and Mycobacteria

“…Nitrofurans 4a–m were tested against Gram-positive ( S. aureus and E. faecium ) or Gram-negative ( E. cloacae , P. aeruginosa , A. baumannii , K. pneumoniae ) pathogens belonging to the so-called ESKAPE panel [ 40 ] of highly virulent and antibiotic resistant bacterial pathogens which are, throughout the world, the major cause of life-threatening nosocomial or hospital-acquired infections in immunocompromised and critically ill patients who are most at risk [ 41 ]. There were two clinically used nitrofuran antibiotics—nitrofurantoin [ 26 ] and furazidine [ 27 ] as well as broad-spectrum fluoroquinoline antibiotic ciprofloxacin [ 42 ] that were used as positive controls and comparators. The compounds were initially screened at a single concentration to determine the presence and the diameter of the bacterial growth inhibition zone around the drug-treated disk.…”